Predicting the outcome of prostate biopsy: comparison of a novel logistic regression‐based model, the prostate cancer risk calculator, and prostate‐specific antigen level alone
暂无分享,去创建一个
Georg Bartsch | Misop Han | Alan W Partin | Samir S Taneja | A. Partin | Misop Han | G. Bartsch | S. Taneja | E. Humphreys | L. Mangold | Elizabeth B Humphreys | Leslie A Mangold | Stacy J Childs | S. Childs | David J Hernandez | D. Hernandez
[1] A. Partin,et al. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. , 1998, Urology.
[2] G Bartsch,et al. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. , 2001, Urology.
[3] H. Carter,et al. PSA velocity for the diagnosis of early prostate cancer. A new concept. , 1993, The Urologic clinics of North America.
[4] M. Kattan,et al. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. , 1999, Urology.
[5] Mesut Remzi,et al. Novel artificial neural network for early detection of prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] David Aaron,et al. A New Concept , 1974 .
[7] Klaus Jung,et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate‐specific antigen levels ≤ 10 ng/ml , 2004, Cancer.
[8] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[9] Klaus Jung,et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.
[10] I. Thompson,et al. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. , 1998, The Journal of urology.
[11] A. Haese*,et al. Development and external validation of an extended 10-core biopsy nomogram. , 2007, European urology.
[12] T. Stamey,et al. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. , 1996, Urology.
[13] M. Kattan,et al. Prostate cancer nomograms: an update. , 2006, European urology.
[14] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[15] I. Thompson,et al. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. , 1997, Urology.
[16] Walter J. Simoneaux,et al. African‐American race is a predictor of prostate cancer detection: incorporation into a pre‐biopsy nomogram , 2006, BJU international.
[17] M. Kattan,et al. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. , 2009, The Journal of urology.
[18] Javier Hernandez,et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. , 2006, Urology.
[19] Ian M Thompson,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.
[20] W. Fair,et al. Incidence and clinical significance of false-negative sextant prostate biopsies. , 1998, The Journal of urology.
[21] Yi-Ching Hsieh,et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL , 2003, Cancer.
[22] G. Pond,et al. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. , 2006, The Canadian journal of urology.
[23] Pierre I Karakiewicz,et al. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. , 2007, European urology.
[24] Carter Hb,et al. PSA velocity for the diagnosis of early prostate cancer. A new concept. , 1993 .
[25] T. Wheeler,et al. Predictors of prostate cancer after initial negative systematic 12 core biopsy. , 2004, The Journal of urology.
[26] M. Kattan,et al. Comparisons of nomograms and urologists' predictions in prostate cancer. , 2002, Seminars in urologic oncology.
[27] M. Kattan,et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. , 2005, The Journal of urology.
[28] A. Haese*,et al. Development and external validation of an extended repeat biopsy nomogram. , 2007, The Journal of urology.
[29] M. Kattan,et al. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. , 2005, The Journal of urology.
[30] T. Stamey,et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. , 2003, The Journal of urology.
[31] Tomohiko Ichikawa,et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. , 2006, Urology.
[32] P. Carroll,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .